# The Human Medicines (Amendments Relating to the Early Access to Medicines Scheme) Regulations 2022, Regulation 4: Amendment of regulation 8


In regulation 8(1) (general interpretation), at the appropriate places insert—
““EAMS medicinal product” means a medicinal product that—
(a) has been included in the Early Access to Medicines Scheme by means of the licensing authority issuing an EAMS scientific opinion in respect of it; and
(b) remains in the scheme by virtue of the EAMS scientific opinion not ceasing to have effect in respect of it by virtue of regulation 167D;”;
““EAMS scientific opinion” is to be construed in accordance with regulation 167C(2)(b);”;
““EAMS scientific opinion holder” means the holder of a EAMS scientific opinion, and accordingly, is the person who places on the market the product to which the opinion relates;”;
““Early Access to Medicines Scheme” means the scheme of that name established and operated under regulation 167C(1);”; and
““EU Clinical Trials Regulation” means Regulation EU No. 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products, and repealing Directive 2001/20/EC;”.

---
Source: https://www.legislation.gov.uk/ukdsi/2022/9780348231892/regulation/4 (the official version)
Page: https://openlegislation.uk/draft-human-medicines-amendments-relating-to-the-early-access-to-medicines-scheme-regulations-2022/regulation-4
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

